Antimycon is a preclinical, proprietary small molecule targeting and inactivating oncoproteins of the Myc family, which are frequently up-regulated in tumor cells. Antimycon is being developed by our Panacela Labs, Inc. subsidiary.
The Myc transcription factor has long been recognized as a highly attractive target for cancer treatment. This mechanism of action is translated into direct tumor-suppressive effect and increased susceptibility of tumors to conventional chemotherapeutic drugs.
Potential indications for Antimycon include treatment of a broad range of solid tumors (breast, prostate, colon, non-small cell lung carcinoma, etc.) and hematological malignancies (various types of leukemia and lymphoma).